Roswell Park Cancer Institute - 665 Elm St - Site 062 — Buffalo, New York

Roswell Park Cancer Institute - 665 Elm St - Site 062 is a clinical research site located in Buffalo, New York, United States 14263.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

Roswell Park Cancer Institute - 665 Elm St - Site 062 has participated in 1 clinical trials.

Therapeutic areas: Solid Tumor.

Sponsors: Kadmon, a Sanofi Company.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Buffalo

Browse all research sites in New York · View every site in Buffalo

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Roswell Park Cancer Institute - 665 Elm St - Site 062?

Roswell Park Cancer Institute - 665 Elm St - Site 062 has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Roswell Park Cancer Institute - 665 Elm St - Site 062 conducted?

Roswell Park Cancer Institute - 665 Elm St - Site 062 has 1 clinical trials on record. Their work covers Solid Tumor.

Is Roswell Park Cancer Institute - 665 Elm St - Site 062 accredited by Crixeo Clinical Trials?

Roswell Park Cancer Institute - 665 Elm St - Site 062 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Roswell Park Cancer Institute - 665 Elm St - Site 062?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.